Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When Will Real World Evidence Be Persuasive? FDA's Temple Offers Perspective

Executive Summary

Postmarketing studies randomized to look at real world data sets could provide the key, Temple suggests; Amgen rep describes use of real world data to support approval of leukemia drug Blincyto.

Advertisement

Related Content

Real-World Evidence Takes Courage: A Conversation With IQVIA’s Nancy Dreyer
Real-World Evidence At US FDA: Bavencio, Blincyto Approvals Point Way Toward Broader Use
Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice
US FDA Officials Provide Primer On 'Real-World' Data
EMA, FDA Talk Real World Evidence, Mutual Recognition, Generic Drugs
Real World Evidence: Between 'Nirvana' And Electronic Roadblocks
Amgen's Blincyto Doubles Survival In TOWER

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel